AC Immune (ACIU) Liabilities and Shareholders Equity (2015 - 2026)

AC Immune (ACIU) has reported Liabilities and Shareholders Equity for 12 consecutive years, with $175.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 74646.66% year-over-year to $175.5 billion; the TTM figure through Mar 2026 stood at $176.1 billion (up 16787.22% YoY), while the FY2025 annual figure was $186.0 million, down 29.42% from the prior year.
• Liabilities and Shareholders Equity improved to $175.5 billion in Q1 2026 per ACIU's latest filing, from $193.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $175.5 billion in Q1 2026 and bottomed at $225087.4 in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $10.5 billion across 5 years, with a median of $206.1 million in 2023.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 95982.08% in 2022 and fell as far as 31.93% in 2022.
• AC Immune's Liabilities and Shareholders Equity stood at $193.0 million in 2022, then gained by 6.78% to $206.1 million in 2023, then rose by 27.9% to $263.6 million in 2024, then declined by 26.78% to $193.0 million in 2025, then jumped by 90828.78% to $175.5 billion in 2026.
• Business Quant data shows ACIU's Liabilities and Shareholders Equity at $175.5 billion in Q1 2026, $193.0 million in Q4 2025, and $214.5 million in Q3 2025.